Rocha, CAfonso, JLago, PArroja, BVieira, AIDias, CCMagro, F2019-05-162019-05-162019Therap Adv Gastroenterol. 2019 Feb 27;12:1756284819828238.http://hdl.handle.net/10400.23/1323The loss of response to adalimumab (ADL) has been related to low serum concentrations at trough. Currently, most methods commercially available for the quantification of ADL are enzyme-linked immunosorbent assay (ELISA) based, with a turnaround time of approximately 8 h, delaying the target dosage adjustment to the subsequent infusion. In this study, we aimed to evaluate the performance of the newly available rapid-test ADL quantification assay by comparing it with three established ELISA methods, using spiked samples and a set of clinical samples.engAdalimumabjournal article10.1177/1756284819828238